Biliary Drainage Plus HAIC in Locally Advanced pCCA

Status Recruiting

Clinical Trial Summary

Biliary drainage and stent placement remains to be the main palliative treatment choice for advanced perihiliar cholangiocarcinoma (pCCA), and the life expectancy is only 4-6 months. Previous single center prospective phase 2 trial showed that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was an encouraging treatment choice for advanced pCCA due to its high tumor control, survival benefit, and low toxicity. Thus, the multicenter prospective controlled trial was designed to explore and confirm the survival benefit of biliary drainage plus hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil compared with biliary drainage plus best support care treatment in locally advanced pCCA patients.

Clinical Trial Description

When a patient is not eligible for surgery, chemotherapy with gemcitabine and cisplatin can be considered for advanced biliary tract cancer. However, in the Advanced Biliary Tract Cancer, or ABC-02 trial in patients with pCCA, the efficacy of this regimen was not significantly higher than that of gemcitabine alone. Therefore, an optimal chemotherapeutic regimen has not been established for this subtype of cholangiocarcinoma. Currently, biliary drainage and stent placement remains to be the main palliative treatment choice, and the life expectancy is only 4-6 months. Previous single center prospective phase 2 trial showed that HAI with oxaliplatin and 5-fluorouracil was an encouraging treatment choice for advanced PCC due to its high tumor control, survival benefit, and low toxicity. So the multicenter prospective controlled trial was designed to explore and confirm the survival benefit of biliary drainage plus hepatic arterial infusion of oxaliplatin and 5-fluorouracil compared with biliary drainage plus best support care treatment in locally advanced pCCA patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05024513
Study type	Interventional
Source	Peking University
Contact	Xiaodong Wang
Phone	18611586227
Email	xiaodongw75@yahoo.com
Status	Recruiting
Phase	Phase 2
Start date	November 1, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04993131` - Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma	N/A
Recruiting	`NCT05546372` - Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma	N/A
Completed	`NCT05402618` - Minimally Invasive Versus Open Surgery for PHC
Recruiting	`NCT05874934` - Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String	N/A
Recruiting	`NCT04561453` - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Active, not recruiting	`NCT05078801` - Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction
Recruiting	`NCT05430698` - PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma	Phase 2
Recruiting	`NCT06125769` - LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)	N/A
Active, not recruiting	`NCT05563870` - Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma	N/A
Recruiting	`NCT04846192` - Prognosis of Nutritional Status for Surgical Peri Hilar Cholangiocarcinoma
Completed	`NCT06357117` - Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma